AVCN 467504
Alternative Names: AVCN-467504Latest Information Update: 09 Oct 2025
At a glance
- Originator Avicanna
- Class Analgesics; Anti-inflammatories; Cannabinoids
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Inflammation; Musculoskeletal pain
Most Recent Events
- 31 Aug 2024 Clinical trials in Inflammation at Unknown location (Topical), before August 2024 (Avicanna pipeline, August 2024)
- 31 Aug 2024 Clinical trials in Musculoskeletal pain at Unknown location (Topical), before August 2024 (Avicanna pipeline, August 2024)
- 27 Aug 2024 USPTO issued the patent covering topical cannabinoid composition and methods for treating musculoskeletal inflammation and pain in USA